Core Viewpoint - Changchun High-tech's stock price has shown fluctuations, with a recent increase of 2.04% and a total market capitalization of 36.804 billion yuan, despite a year-to-date decline of 2.52% [1] Financial Performance - For the period from January to September 2025, Changchun High-tech reported operating revenue of 9.807 billion yuan, a year-on-year decrease of 5.60%, and a net profit attributable to shareholders of 1.165 billion yuan, down 58.23% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 4.63% to 104,100, while the average number of circulating shares per person increased by 4.85% to 3,840 shares [2] Dividend Distribution - Since its A-share listing, Changchun High-tech has distributed a total of 4.791 billion yuan in dividends, with 3.259 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.307 million shares to 9.7451 million shares, while other institutional investors like Huatai-PB CSI 300 ETF and others have reduced their holdings [3]

Group 1: Financial Performance - Hengyu Environmental reported a revenue of 294 million yuan for 2025, an increase of 89.87%, and a net profit of 35.93 million yuan, up 106.25% [1] - Zhongke Shuguang achieved a revenue of 14.97 billion yuan in 2025, growing by 13.86%, with a net profit of 2.113 billion yuan, reflecting a 10.54% increase [2] - Oat Technology's revenue reached 619 million yuan, marking a 24.33% growth, and a net profit of 137 million yuan, up 42.63% [4] - Yongxi Electronics reported a revenue of 4.4 billion yuan, a 21.92% increase, with a net profit of 82.24 million yuan, up 23.99% [5] Group 2: Shareholder Actions - Yashida Optoelectronics announced that a shareholder plans to reduce holdings by up to 1.6 million shares, representing no more than 0.976% of the total share capital [3] - Yuanli Co. intends to repurchase shares worth 50 to 60 million yuan for employee stock ownership plans, with a maximum repurchase price of 20 yuan per share [6] - Conch Cement's controlling shareholder plans to increase holdings by 700 million to 1.4 billion yuan [7] - Huaneng Hydropower's controlling shareholder plans to increase holdings by 100 to 150 million yuan [8] Group 3: Corporate Announcements - Baotai's drug application for Darpobatin injection has been accepted by the National Medical Products Administration [14] - Changchun High-tech's subsidiary received approval for clinical trials of GenSci141 ointment [15] - Tongwei Co. is planning to acquire 100% of Lihua Qingneng, with stock trading suspended for up to 10 trading days [16] - Guoyao Modern's application for the raw material drug Minaprine has been approved [20] Group 4: Market Activities - Kaipu Cloud announced the termination of the acquisition of Nanning Taike [21] - Boji Pharmaceutical plans to reduce its holdings by up to 0.69% of the total share capital [23] - ST Renfu intends to issue shares to its controlling shareholder to raise 3 to 3.5 billion yuan for innovative drug development projects [24] - Huayi Technology submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [25]

Core Viewpoint - The company, Changchun High-tech Industry (Group) Co., Ltd., announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of GenSci141 ointment, which is aimed at treating conditions related to hypogonadism and congenital adrenal hyperplasia in children [1][2]. Group 1: Drug Information - The product name is GenSci141 ointment, which is a dihydrotestosterone ointment classified as a chemical drug of categories 2.2 and 2.4 [2]. - The clinical trial application for GenSci141 ointment has been approved, allowing the company to proceed with the necessary clinical studies [1]. - The indications for GenSci141 ointment include improving conditions caused by hypergonadotropic hypogonadism, 5α-reductase deficiency, and congenital adrenal hyperplasia, as well as idiopathic causes leading to small penis in children [1][2]. Group 2: Market Context - Current treatment methods for small penis in children include medication, surgery, and psychological counseling, with medication being the primary approach [2]. - There has been no approved medication specifically for the treatment of small penis in children until now, highlighting the potential market opportunity for GenSci141 ointment [2]. Group 3: Company Strategy - The company will actively promote the development of the aforementioned research project and will comply with relevant regulations to disclose subsequent progress in a timely manner [4].

Core Viewpoint - The announcement highlights that Changchun High-tech Industry (Group) Co., Ltd.'s subsidiary, GenSci Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of GenSci141 ointment, which is aimed at treating specific conditions related to male genital development [1][2]. Group 1: Drug Information - The product name is GenSci141 ointment, which is a dihydrotestosterone ointment classified as a chemical drug of categories 2.2 and 2.4 [2]. - The clinical trial application was approved under acceptance numbers CXHL2501394, CXHL2501395, CXHL2501396, and CXHL2501397 [1]. - The ointment is intended for conditions such as hypogonadotropic hypogonadism, 5α-reductase type 2 deficiency, congenital adrenal hyperplasia, and idiopathic causes leading to penile underdevelopment in children [1][2]. Group 2: Market Context - Current treatment methods for penile underdevelopment in children include medication, surgery, and psychological counseling, with medication being the primary approach [2]. - There has been no approved medication specifically for improving penile development in children until now, indicating a potential market opportunity for GenSci141 ointment [2]. Group 3: Company Strategy - The company plans to actively advance the research and development of the GenSci141 ointment and will adhere to relevant regulations for timely information disclosure regarding the project's progress [4].

证券日报网讯 2月24日，长春高新发布公告称，近日，公司子公司——长春金赛药业有限责任公司（简 称"金赛药业"）收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业 GenSci141软膏境内生产药品注册临床试验申请获得批准。 （文章来源：证券日报） ...

该药品适应症：用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先 天性肾上腺皮质增生症、特发性的原因导致的儿童小阴茎。 长春高新（000661）(000661.SZ)公告，公司子公司——长春金赛药业有限责任公司(简称"金赛药业")收 到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci141软膏境内生产药 品注册临床试验申请获得批准。 ...

格隆汇2月24日丨长春高新(000661.SZ)公布，子公司——长春金赛药业有限责任公司（简称"金赛药 业"）收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci141软膏境内 生产药品注册临床试验申请获得批准。GenSci141软膏是金赛药业研发的一款双氢睾酮软膏，属于化学 药品2.2类、2.4类。 ...

证券代码：000661 证券简称：长春高新 公告编号：2026-010 长春高新技术产业（集团）股份有限公司 关于子公司 GenSci141 软膏境内生产药品注册临床试验申请 获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品监督 管理局核准签发的《药物临床试验批准通知书》，金赛药业 GenSci141 软膏境内 生产药品注册临床试验申请获得批准，现将相关情况公告如下： 一、药品的基本情况 产品名称：GenSci141 软膏 申请人：长春金赛药业有限责任公司 审批结论：经审查，同意本品开展临床试验 适应症：用于改善因高促性腺激素性性腺功能减退症、5α-还原酶 2 缺乏症、 雄激素合成减少的先天性肾上腺皮质增生症、特发性的原因导致的儿童小阴茎。 二、药品的其它情况 GenSci141 软膏是金赛药业研发的一款双氢睾酮软膏，属于化学药品 2.2 类、 2.4 类。 儿童小阴茎的治疗方法包括药物治疗、手术治疗及心理疏导等 ...

该药品适应症：用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先 天性肾上腺皮质增生症、特发性的原因导致的儿童小阴茎。 智通财经APP讯，长春高新(000661.SZ)公告，公司子公司——长春金赛药业有限责任公司(简称"金赛药 业")收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci141软膏境内 生产药品注册临床试验申请获得批准。 ...

Core Viewpoint - The announcement indicates that the subsidiary of Changchun High-tech, Jinsai Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of GenSci141 ointment, a product developed by the company [1] Group 1 - Jinsai Pharmaceutical has obtained the Clinical Trial Approval Notice for GenSci141 ointment [1] - GenSci141 ointment is a dihydrotestosterone ointment classified as a chemical drug of categories 2.2 and 2.4 [1]